Patients with breast cancer at long-term increased risk of first depression
the ONA take:
According to a new study published in Journal of Clinical Oncology, women with breast cancer are at an increased long-term risk for developing first depression.
The researchers sought to investigate the risk of first depression by determining the incidence of hospital contact as a result of severe episodes of depression and the incidence of antidepressant use. Researchers used Danish national registries to identify nearly 2 million women no diagnosis of cancer or a major psychiatric disorder.
Researchers followed these patients from 1998 and 2011. In the 13-year time period, nearly 45,000 women were diagnosed with breast cancer. Within 1 year after cancer diagnosis, hospital contact had a rate ratio of 1.70 (95% CI, 1.41 - 2.05) and antidepressant use had a rate ratio of 3.09 (95% CI, 2.95 - 3.22). At 3 and 8 years, both rate ratios were significantly elevated.
The researchers also identified various factors associated with the use of antidepressants, including basic and vocational education levels, comorbidity, living alone, node-positive disease, and older age, which the researchers recommend clinicians be aware of.
Women with breast cancer are at an increased long-term risk for developing first depression.
Purpose of this study is to investigate the risk for first depression, assessed as incident hospital contacts for depression and incident use of antidepressants, among women with breast cancer. Women with breast cancer are at long–term increased risk for first depression, including both severe episodes leading to hospital contact and use of antidepressants.
Clinicians should be aware that the risk is highest in women with comorbid conditions, node–positive disease, and age of 70 years or more. The authors found no clear association between type of surgery or adjuvant treatment and risk for depression.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|